학술논문
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Document Type
Article
Author
Yau, Thomas ; Park, Joong-Won; Finn, Richard S; Cheng, Ann-Lii; Mathurin, Philippe; Edeline, Julien; Kudo, Masatoshi; Harding, James J; Merle, Philippe; Rosmorduc, Olivier; Wyrwicz, Lucjan; Schott, Eckart; Choo, Su Pin; Kelley, Robin Kate; Sieghart, Wolfgang; Assenat, Eric; Zaucha, Renata; Furuse, Junji; Abou-Alfa, Ghassan K; El-Khoueiry, Anthony B; Melero, Ignacio; Begic, Damir; Chen, Gong; Neely, Jaclyn; Wisniewski, Tami; Tschaika, Marina; Sangro, Bruno
Source
In The Lancet Oncology January 2022 23(1):77-90
Subject
Language
ISSN
1470-2045